NeoGenomics, Inc. revised earnings guidance for the fiscal year 2023. For the year, the company expects consolidated revenue to be in the range of $565 million to $575 million against previous guidance range of $555 million to $565 million. Net loss to be in the range of $107 million to $100 million against previous guidance range of $116 million to $108 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.63 USD | -0.89% | +0.77% | -3.40% |
May. 02 | North American Morning Briefing : Stock Futures -3- | DJ |
Apr. 30 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.40% | 2B | |
-13.90% | 8.58B | |
+60.25% | 4.12B | |
-3.34% | 2.48B | |
-10.16% | 2.44B | |
-43.01% | 2.29B | |
-19.79% | 1.53B | |
-40.57% | 1.21B | |
+9.11% | 1.12B | |
+12.53% | 940M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023